Table 2.
Change in symptoms, therapy and visual analogue scale (VAS) ratings between T0 and T1 (n = 35)
| T0 | T1 | p-value | |
|---|---|---|---|
| Upper airway symptoms |
28 (80%) |
9 (26%) |
<0.001 |
| Asthma symptoms |
34 (97%) |
20 (57%) |
<0.001 |
| Use of asthma medication* |
31 (91%) |
19 (56%) |
0.002 |
| Short acting beta2 agonists |
19 (56%) |
13 (38%) |
0.18 |
| Long acting beta2 agonists |
10 (29%) |
10 (29%) |
1.0 |
| Inhalable corticosteroids |
26 (76%) |
10 (29%) |
<0.001 |
| Smokers |
10 (29 %) |
14 (40%) |
0.05 |
| VAS (cm) health status |
1.2 (2.9) |
8.0 (4.0) |
<0.001 |
| VAS (cm) overall satisfaction | 2.1 (6.1) | 8.3 (3.4) | <0.001 |
Legend: Upper airway symptoms (conjunctivitis, rhinitis, hoarseness, pharyngeal irritant sensations); asthma symptoms (irritation, wheezing, chronic cough, chest tightness and dyspnoea); VAS = visual analogue scale. Data is presented as mean ± SD, median and interquartile range (IQR) or number (%).
*n = 34.